Hotgen Biotech’s SGC001 Receives NMPA Approval for Clinical Trials in Myocardial Infarction

Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb), SGC001. This emergency use mAb is intended for the treatment of anterior ST segment elevation myocardial infarction (STEMI). Notably, SGC001 has already been cleared for trials in the US and is positioned as an emergency treatment for patients with acute myocardial infarction (AMI). Currently, there is no similar product in the clinical development pipeline or approved for marketing, highlighting the potential significance of SGC001 in addressing this critical medical need.- Flcube.com